Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab

QR Code

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Aline Lissa Okita, Tatiane Benini, Denise Reis Longhi
Format:	article
Langue:	EN
Publié:	Mattioli1885 2020
Sujets:	severe psoriasis biologics secukinumab adalimumab ustekinumab Dermatology RL1-803
Accès en ligne:	https://doaj.org/article/985fde7fec8c4cf2bc426b7226432f67
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Secukinumab in the treatment of psoriasis: patient selection and perspectives
par: Yang EJ, et autres
Publié: (2018)

A Rare Infectious Complication of a Treatment with Biologics: Disseminated Cutaneous Leishmaniasis Associated with Adalimumab
par: Kerasia-Maria Plachouri, et autres
Publié: (2020)

Clinical evidence of therapy for genital psoriasis by biologic agents
par: Evgeny V. Sokolovskiy, et autres
Publié: (2021)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
par: Matsumoto S, et autres
Publié: (2018)

Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis
par: Anzengruber F, et autres
Publié: (2018)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
par: Hampton P, et autres
Publié: (2021)

Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population
par: Berman J, et autres
Publié: (2021)

Fetal Acrania (Exencephaly) in the Context of a Pregnant Female Taking Adalimumab for Psoriasis: A Case Report
par: Daham N, et autres
Publié: (2020)

Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India
par: Budamakuntla L, et autres
Publié: (2019)

Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients
par: Anani HAA, et autres
Publié: (2020)

A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
par: Byron P. Vaughn
Publié: (2021)

Pustular psoriasis: pathophysiology and current treatment perspectives
par: Benjegerdes KE, et autres
Publié: (2016)

Updates on the Treatment of Erythrodermic Psoriasis
par: Lo Y, et autres
Publié: (2021)

Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis
par: Nicolazzo D, et autres
Publié: (2014)

Psoriasis and alcohol
par: Svanström C, et autres
Publié: (2019)

Dermoscopic hemorrhagic dots: an early predictor of response of psoriasis to biologic agents
par: Aimilios Lallas, et autres
Publié: (2016)

Systematic review of immunomodulatory therapies for hidradenitis suppurativa
par: Lim SYD, et autres
Publié: (2019)

Psoriasis and uveitis: links and risks
par: Fotiadou C, et autres
Publié: (2019)

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
par: D'Angelo S, et autres
Publié: (2017)

Management of scalp psoriasis: current perspectives
par: Blakely K, et autres
Publié: (2016)

The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
par: M. Panahi, et autres
Publié: (2021)

Psoriasis: Targets and Therapy
Publié: (2012)

Correlation Between Psoriasis Severity and Nonalcoholic Fatty Liver Disease Degree Measured Using Controlled Attenuation Parameter
par: Gandha N, et autres
Publié: (2020)

Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
par: Annunziata Dattola, et autres
Publié: (2021)

Diagnosis and screening of patients with generalized pustular psoriasis
par: Ly K, et autres
Publié: (2019)

Current knowledge on psoriasis and autoimmune diseases
par: Ayala-Fontánez N, et autres
Publié: (2016)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
par: Machado Á, et autres
Publié: (2018)

Ustekinumab-induced chronic lymphocytic leukemia in a patient with psoriatic arthritis
par: Fusun Gediz, et autres
Publié: (2021)

An Atypical Case of Pustular Psoriasis Presenting With Severe Subungual Abscesses Involving All Fingers
par: A. Tulin Mansur
Publié: (2019)

Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health
par: Teklu M, et autres
Publié: (2021)

Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic
par: Haulrig MB, et autres
Publié: (2021)

The new external drug for the treatment of psoriasis based on inhibition of serine proteases
par: Alexander S. Zhukov, et autres
Publié: (2021)

Serum TSLP is a potential biomarker of psoriasis vulgaris activity
par: El-Ghareeb MI, et autres
Publié: (2019)

Assessment and monitoring of biologic drug adverse events in patients with psoriasis
par: Hanley T, et autres
Publié: (2016)

Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection
par: Madani A, et autres
Publié: (2021)

Erythrodermic psoriasis: pathophysiology and current treatment perspectives
par: Singh RK, et autres
Publié: (2016)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
par: Riccardo G. Borroni, et autres
Publié: (2021)

Prevalence of Metabolic Syndrome and Its Parameters and Their Correlations With Psoriasis Duration, Severity, and Sleep Quality In Psoriasis Patients: A Cross-Sectional Study
par: Betul Tas, et autres
Publié: (2021)

Phosphodiesterase-4 Inhibition in Psoriasis
par: Milakovic M, et autres
Publié: (2021)

Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device in facilitating the removal of scales after topical application in patients with psoriasis corporis or psoriasis capitis
par: Hengge UR, et autres
Publié: (2017)